This review highlights the complex, often opposing roles of ETA and ETB receptors in cardiovascular disease and the ongoing uncertainty regarding the optimal selectivity of endothelin receptor antagonists.
No takes yet. Share an insight, caveat, or question.
Endothelin antagonists should not yet change practice in cardiovascular disease; leaves open optimal ETA/ETB selectivity.
Schneider et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: